HOWL Werewolf Therapeutics Inc

Price (delayed)

$0.4324

Market cap

$21.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$12.21M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its ...

Highlights
HOWL's EPS is up by 27% YoY and by 9% from the previous quarter
The company's net income rose by 22% YoY and by 7% QoQ
Werewolf Therapeutics's revenue has plunged by 100% YoY
The gross profit has plunged by 100% YoY

Key stats

What are the main financial stats of HOWL

HOWL stock price

How has the Werewolf Therapeutics stock price performed over time
Intraday
2.34%
1 week
-5.18%
1 month
-37.33%
1 year
-66.99%
YTD
-31.74%
QTD
-48.07%

Financial performance

How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.96M
Net income
-$56.27M
Gross margin
N/A
Net margin
N/A
Werewolf Therapeutics's revenue has plunged by 100% YoY
The gross profit has plunged by 100% YoY
Werewolf Therapeutics's operating income has increased by 25% YoY and by 8% QoQ
The company's net income rose by 22% YoY and by 7% QoQ

Price vs fundamentals

How does HOWL's price correlate with its fundamentals

Growth

What is Werewolf Therapeutics's growth rate over time

Valuation

What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
1.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HOWL's EPS is up by 27% YoY and by 9% from the previous quarter
The equity has plunged by 79% YoY and by 51% from the previous quarter
HOWL's price to book (P/B) is 24% lower than its last 4 quarters average of 2.2 but 12% higher than its 5-year quarterly average of 1.5
Werewolf Therapeutics's revenue has plunged by 100% YoY

Efficiency

How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has shrunk by 133% YoY and by 31% QoQ
Werewolf Therapeutics's return on assets has decreased by 37% YoY and by 8% QoQ
HOWL's ROIC is down by 31% YoY and by 21% QoQ

Dividends

What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOWL.

Financial health

How did Werewolf Therapeutics financials performed over time
The total assets is 27% higher than the total liabilities
The quick ratio has dropped by 85% year-on-year and by 23% since the previous quarter
HOWL's current ratio has dropped by 84% year-on-year and by 22% since the previous quarter
HOWL's debt to equity has soared by 103% from the previous quarter
The equity has plunged by 79% YoY and by 51% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.